peptide wiki

Mechanism

Pre-mixed blend of two mitochondria-targeted peptides marketed for cellular energy and metabolic support. SS-31 (elamipretide) is a tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, stabilizing cristae structure, reducing oxidative stress, and supporting ATP production. MOTS-c is a mitochondrial-derived peptide that activates AMPK metabolic signaling and influences glucose and lipid handling. SS-31 itself gained a narrow FDA approval (Forzinity, 2025) for Barth syndrome, but MOTS-c remains a research compound, and there is no controlled human efficacy or safety data for this specific combination — the blend is sold grey-market, not as the approved indication.

Studied uses

• mitochondrial function and cellular energy support (research only)
• metabolic, exercise-capacity, and anti-aging interest (research only)
• recovery from oxidative or metabolic stress (research only)

Identification

Typical dose	Vendor-dependent; component norms: SS-31 commonly 5-25 mg/day subcutaneous in research/clinical use; MOTS-c 5-10 mg 1-3x/week subcutaneous. No validated combination dosing exists.
Half-life	SS-31: terminal half-life roughly 3-6 hours (subcutaneous, human clinical data); MOTS-c: short, not well characterized in humans

Safety

This blend is not FDA-approved; it is sold as a research-only / grey-market product. SS-31 is FDA-approved only as Forzinity for Barth syndrome, not as a general metabolic or anti-aging agent and not in combination with MOTS-c. No combination-specific human safety data. Not evaluated by WADA as a blend.